14:48 | Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs |  |
08/08 | Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce In.. |  |
08/08 | Eli Lilly and Company Announces the Availability of a New, Citrate-Free Formulation of .. |  |
08/08 | Eli Lilly May Divert Employment Outside Indiana After US State OKs Abortion Bill |  |
06/08 | Biden team, Eli Lilly condemn new Indiana abortion ban |  |
05/08 | Eli Lilly Stock Outlook Unchanged After Q2 Update But 'Mixed Elements' to Consider, Gol.. |  |
05/08 | PUMP / DUMP #40 : This week's gainers and losers |  |
05/08 | Another case of good news is bad news |  |
04/08 | MÄRKTE USA/Wall Street uneinheitlich - Ölpreise im freien Fall |  |
04/08 | ELI LILLY & CO Management's Discussion and Analysis of Results of Operations and
Finan.. |  |
04/08 | GLOBAL MARKETS LIVE : Bayer, Merck, eBay, MetLife, Eli Lilly... |  |
04/08 | TRANSCRIPT : Eli Lilly and Company, Q2 2022 Earnings Call, Aug 04, 2022 |  |
04/08 | Eli Lilly Lowers 2022 Profit Outlook on Foreign Exchange Headwinds as Second-Quarter Re.. |  |
04/08 | Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results |  |
04/08 | SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday |  |
04/08 | Still seeing the glass half full |  |
04/08 | El fármaco contra el Alzheimer de Lilly podría obtener una rápida aprobación de la FDA .. |  |
04/08 | SECTOR UPDATE : Health Care |  |
04/08 | MARKETSCREENER'S WORLD PRESS REVIEW : August 4, 2022 |  |
04/08 | ELI LILLY AND : Q2 2022 Financial Workbook |  |
04/08 | ELI LILLY AND : Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New.. |  |
04/08 | Eli Lilly Trims FY22 EPS Guidance Amid Weaker Q2 Results |  |
04/08 | Eli Lilly verlaagt outlook weer |  |
04/08 | Eli Lilly and Company's Q2 Adjusted Earnings, Revenue Fall |  |
04/08 | ELI LILLY AND : Q2 2022 Lilly Press Release |  |
04/08 | LILLY : Q2 Earnings Snapshot |  |
04/08 | Eli Lilly quarterly profit falls 31% on diabetes drug weakness |  |
04/08 | GUIDANCE : (LLY) ELI LILLY AND COMPANY Expects Fiscal Year 2022 EPS Range $7.90 - $8.05 |  |
04/08 | Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines an.. |  |
04/08 | Earnings Flash (LLY) ELI LILLY AND COMPANY Posts Q2 Revenue $6.49B |  |
04/08 | Earnings Flash (LLY) ELI LILLY AND COMPANY Reports Q2 EPS $1.25 |  |
04/08 | Eli Lilly and Company Revises Earnings Guidance for the Year 2022 |  |
04/08 | BOLSA DE MADRID : La tecnología está cansada de ir cuesta abajo |  |
04/08 | Eli Lilly Seeks US Approval for Direct Sale of COVID-19 Antibody to Healthcare Faciliti.. |  |
03/08 | Eli Lilly to make COVID-19 antibody drug commercially available from August |  |
03/08 | Eli Lilly Says Intends To Make Bebtelovimab Commercially Available For Purchase By U.S... |  |
01/08 | Optimism returns |  |
01/08 | BOLSA DE MADRID : Fuegos de artificio en julio |  |
22/07 | Lilly's Diabetes Drug Mounjaro Gets EU Medicines Agency Panel's Recommendation |  |
21/07 | Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Annou.. |  |
20/07 | Auron Therapeutics, Inc. announced that it has received $48 million in funding from a g.. |  |
18/07 | Erasca Working With Eli Lilly in Oncology Clinical Trial |  |
18/07 | Delfi Diagnostics, Inc. announced that it has received $224.999901 million in funding f.. |  |
14/07 | Triastek Announces Research Collaboration with Lilly to Explore the Application of 3D P.. |  |
14/07 | Auron Therapeutics, Inc. announced that it expects to receive funding |  |
12/07 | Investors are bracing for earnings season |  |
12/07 | ANALYST RECOMMENDATIONS : Blackrock, Eli Lilly, Hammerson, Mondelez, Twitter... |  |
01/07 | Pharmaceutical companies still have the upper hand |  |
29/06 | GLOBAL MARKETS LIVE : Novartis, Tesla, Disney, Sony, Walmart... |  |
29/06 | Eli Lilly and Company to Supply an Additional 150,000 Doses of Abcellera-Discovered Ant.. |  |
29/06 | Confidence is key |  |
29/06 | Eli Lilly Bags $275 Million Deal to Supply Additional Doses Of COVID-19 Antibody Drug i.. |  |
29/06 | Eli Lilly to Provide US Government With Additional 150,000 Doses of COVID-19 Treatment .. |  |
29/06 | Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ong.. |  |
29/06 | Eli Lilly and Company Will Supply an Additional 150,000 Doses of Bebtelovimab to U.S. G.. |  |
29/06 | Eli Lilly Gets $275 Million U.S. Pact for Covid-19 Antibody Drug |  |
27/06 | Lilly Declares Third-Quarter 2022 Dividend |  |
27/06 | Eli Lilly and Company Declares Third-Quarter Dividend for 2022, Payable on September 9,.. |  |
27/06 | Eli Lilly, Innovent's Tyvyt Obtains Approval to Treat Advanced Gastric, Gastroesophagea.. |  |
27/06 | Innovent Biologics, Inc. and Eli Lilly and Company Jointly Announces Approval of TYVYT .. |  |
22/06 | AVEO Pharmaceuticals, Eli Lilly Partner in Clinical Trial to Assess Potential Treatment.. |  |
22/06 | Aveo Pharmaceuticals, Inc. Announces Clinical Trial Collaboration and Supply Agreement .. |  |
22/06 | AVEO Oncology in Collaboration, Supply Agreement With Eli Lilly |  |
21/06 | Eli Lilly, Innovent's Tyvyt Gets Approval for Treatment of Esophageal Cancer in China |  |
21/06 | Innovent and Lilly Jointly Announce the Approval of TYVYT (sintilimab injection) by Chi.. |  |
17/06 | Sidekick Enters Strategic Collaboration with Lilly to Support Patients with Breast Canc.. |  |
14/06 | TRANSCRIPT : Eli Lilly and Company Presents at Goldman Sachs 43rd Annual Global Healthcare.. |  |
14/06 | Eli-Lilly-Medikament gegen Kreisrunden Haarausfall in USA zugelassen |  |
14/06 | Eli Lilly, Incyte Win US FDA Approval For Alopecia Areata Treatment |  |
14/06 | Eli Lilly, Incyte Say FDA Approves Olumiant for Treatment of Alopecia Areata in Adults |  |
13/06 | FDA Grants the Approval of First Systemic Treatment for Alopecia Areata to Eli Lilly an.. |  |
13/06 | Eli Lilly Signs License Deal With DE Shaw Research |  |
13/06 | FDA Approves Eli Lilly's Olumiant Oral Tablets for Alopecia |  |
10/06 | Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs |  |
10/06 | Delfi Diagnostics, Inc. announced that it expects to receive $224.999901 million in fun.. |  |